Quintiles forms drug research alliance with South African medical center
Quintiles
Related Stories
- Quintiles vaults to 16th on '100 Best Places to Work in IT' list
- Pfizer honors Quintiles award for data management services
- 'We've really come a long way, baby;' Quintiles dedicates new headquarters
- Quintiles lab launches genetic tests targeting individualized cancer treatments
- Quintiles names new leader for market intelligence practice
- Former Eli Lilly exec to lead Quintiles subsidiary Innovex
Related Blog Posts
- Quintiles exec: H1N1 vaccine expected in October
- In IT world, it's more than pay that keeps employees motivated, survey shows
On The Web
Site Search
Get the latest news alerts: Follow LTW at Twitter.
Local Tech Wire
RESEARCH TRIANGLE PARK, N.C. – Quintiles is expanding the reach of its drug research and development efforts to South Africa.
The contract research organization firm which is a provider of clinical trials, consulting services and investment capital to life science companies around the world has formed an alliance with the University of Pretoria as part of its Prime Site program.
Quintiles, which recently opened an operation in Ghana, will work with the South African medical center on potential drug candidates. Quintiles also has Prime Site agreements in place with Washington Hospital Center in Washington, D.C. and Queen Mary’s College in London.
Financial terms of the agreement with the University of Pretoria were not disclosed.
"Prime Sites are large clinical institutions that collaborate with Quintiles to enhance their infrastructure for conducting clinical trials,” said Quintiles’ Christopher Cabell, head of Global Access to Patients. "The University of Pretoria was selected because of its experience in conducting clinical research, its access to substantial patient populations and clinical expertise all across multiple therapeutic areas. Through this new partnership Quintiles will be able to significantly improve its ability to access patients and investigators who are critical to facilitating the increasingly complex therapies under development."
Quintiles has launched seven drug studies this year and another six are already scheduled at its first two Prime Sites.
Featured
Hot Off The Wire
- Red Hat's new Fedora lead; Cree LED breakthrough; Google, Cisco top 'green' list; Oracle rejects SAP settlement; Yahoo board shakeup
- Will Cisco report progress in its turnaround efforts?
- Cisco server fire threat; Lenovo Android upgrade; cloud startup vs. Cisco; Epic's Blesinski to host awards; Google 'Solve for X'
E-mail Preferences
The Skinny
- Epic Games' Tim Sweeney reaps arts Hall of Fame honor today
- Charlotte's startup efforts pick up steam as more data pours in
- 'Battle in Bay 7' returns - Are you techies ready for some basketball?
- Inside RTP's new angel fund: Founders meeting 'significant' need
- Who won 'Social Bowl'? Super Bowl ads paying fans to play
- RTP broadband firm Overture, minus two top execs, launches new look
- Will RTP-based ChannelAdvisor go public? They're thinking
- What brands are winning Super Bowl hype? Two Durham firms to find out
- In Super Bowl of social media, Patriots win, Triangle firm says
- Big job cuts coming at IBM? Don't be surprised